

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

1100 NEW YORK AVENUE, N.W., SUITE 600
WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE: (202) 371-2540; (202) 371-6566

ROBERT GREENE STERNE
EDWARD J. KESSLER
JORGE A. GOLDSTEIN
SAMUEL L. FOX
DAVID K.S. CORNWELL
ROBERT W. EDMOND
TRACY-GENE G. DURKIN
MICHELE A. CIMBALA
JEL B. RAY
ROBERT E. SOKOHL

ERIC K. STEFFE
MICHAEL O. LEE
STEVEN R. LUDWIG
JOHN M. COVERT*
LINDA E. ALCORN
RAZ E. FLESHNER
ROBERT C. MILLONIG
MICHAEL V. MESSINGER
JUDITH U. KIM
TIMOTHY J. SHEA, JR.

DONALD R. MCPHAIL
PATRICK E. GARRETT
STEPHEN G. WHITESIDE
NOEL B. WHITLEY
JEFFREY T. HELVEY*
HEIDI L. KRAUS
JEFFREY R. KURIN
RAYMOND MILLIEN
PATRICK D. O'BRIEN
BRIAN S. ROSENBLUM

LAWRENCE B. BUGAISKY
CRYSTAL D. SAYLES*
EDWARD W. YEE
ALBERT L. FERRO*
DONALD R. BANOWITZ*
PETER A. JACKMAN*
MOLLY A. McCALL*
TERESA U. MEDLER*
JEFFREY S. WEAVER*

DONALD J. FEATHERSTONE
KAREN R. MARKOWICZ**
GRANT E. REED**
SUZANNE E. ZISKA**
BRIAN J. DEL BUONO**
CAMERON H. TOUSI**
VINCENT L. CAPUANO**
ROBERT H. BENSON*
OF COUNSEL

09/340690
06/29/99



June 29, 1999

WRITER'S DIRECT NUMBER:
(202) 789-5509

Box Patent Application

Assistant Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Non-Provisional Utility Patent Application under 37 C.F.R. § 1.53(b)
Appl. No. To be assigned; Filed: Herewith
(Divisional of Appl. No. 08/741,095; Filed: October 30, 1996)
For: **Human Tumor Necrosis Factor Receptor-Like 2**
Inventors: Ni *et al.*
Our Ref: 1488.0770007/EKS/SGW

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

1. USPTO Utility Patent Application Transmittal Form PTO/SB/05;
2. Fee Transmittal (Form PTO/SB/17) (*in duplicate*);
3. 37 C.F.R. § 1.136(a)(3) Authorization to Treat a Reply As Incorporating An Extension of Time (*in duplicate*);
4. U.S. Utility Patent Application entitled:

Human Tumor Necrosis Factor Receptor-Like 2

Assistant Commissioner for Patents
June 29, 1999
Page 2

and naming as inventors:

Jian Ni
Craig A. Rosen
Reiner L. Gentz
Sally Doreen Patricia Lyn
Mark Robert Hurle

the application comprising:

a. A specification containing:

- (i) 84 pages of description prior to the claims;
- (ii) 20 pages of sequence listing;
- (iii) 8 pages of claims (Claims 1-26);
- (iv) a one (1) page abstract;

b. 27 sheets of drawings: (Figures 1A, 1B, 2, 3, 4A, 4B, 5, 6, 7A, 7B, 8-12, 13A-13C, 14A-14C, 15A-15E, and 16);

5. A copy of the executed Declaration, as filed in U.S. Appl. No. 08/741,095, by Jian Ni, Craig A. Rosen, and Reiner L. Gentz;
6. A copy of the executed Declaration, as filed in U.S. Appl. No. 08/741,095, by Sally Doreen Patricia Lyn and Mark Robert Hurle;
7. First Preliminary Amendment;
8. Second Preliminary Amendment and Submission of Sequence Listing with Exhibits A and B;
9. ATCC Deposit Receipt for Deposit Nos. 97057, 97058, and 97059;
10. Computer Readable Copy of Sequence Listing;
11. Paper Copy of Sequence Listing (Pages 85-106);

Assistant Commissioner for Patents
June 29, 1999
Page 3

12. Our Check No. 24788 in the amount of \$4,906.00 for:

- (i) \$ 760.00 Basic Utility Filing Fee (37 C.F.R. § 1.16(a));
- (ii) \$1,482.00 Independent Claims in Excess of Three (37 C.F.R. § 1.16(b));
- (iii) \$2,664.00 Claims in excess of twenty (37 C.F.R. § 1.16(c)); and

13. Two (2) return postcards.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Stephen G. Whiteside
Attorney for Applicants
Registration No. 42,224

Enclosures

077-7.DIV.TRANS.WPD
SKGF Rec. 9/22/98dcw

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL <i>(Only for new nonprovisional applications under 37 CFR § 1.53(b))</i>		Attorney Docket No.	1488.0770007/EKS/SGW
		First Inventor or Application Identifier	Jian Ni
		Title	Human Tumor Necrosis Factor Receptor-Like 2
		Express Mail Label No.	

APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents.</i>		Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
--	--	--

1. * Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)

2. Specification [Total Pages 113]
(preferred arrangement set forth below)
- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

3. Drawing(s) (35 U.S.C. 113) [Total Sheets 27]

4. Oath or Declaration [Total Pages 6]
a. Newly executed (original or copy)
b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed)
[Note Box 5 below]
i. **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).

5. Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. Microfiche Computer Program (*Appendix*)

7. Nucleotide and/or Amino Acid Sequence Submission (*if applicable, all necessary*)
a. Computer Readable Copy
b. Paper Copy (identical to computer copy)
c. Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. Assignment Papers (cover sheet & document(s))

9. 37 CFR 3.73(b) Statement Power of Attorney (when there is an assignee)

10. English Translation Document (*if applicable*)

11. Information Disclosure Copies of IDS Citations Statement (IDS)/PTO-1449

12. First Preliminary Amendment;
Second Preliminary Amendment and Submission of Sequence Listing

13. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)

14. *Small Entity Statement(s) Statement filed in prior application, Status still proper and desired
(PTO/SB/09-12)

15. Certified Copy of Priority Document(s)
(if foreign priority is claimed)

16. Other: 37 C.F.R. § 1.136(a)(3) Authorization
 Other:

*NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27). EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).


17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

Continuation Divisional Continuation-in-Part (CIP) of prior application No: 08/741,095

Prior application information: Examiner Draper, G. Group/Art Unit: 1646

18. CORRESPONDENCE ADDRESS

<input type="checkbox"/> Customer Number or Bar Code Label <i>(Insert Customer No. or Attach bar code label here)</i>		or <input checked="" type="checkbox"/> Correspondence address below
NAME	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. Attorneys at Law		
ADDRESS	Suite 600, 1100 New York Avenue, N.W.		
CITY	Washington	STATE	DC
COUNTRY	USA	TELEPHONE	(202) 371-2600
ZIP CODE	20005-3934		
FAX	(202) 371-2540		

NAME (Print/Type)	Stephen G. Whiteside	Registration No. (Attorney/Agent)	42,224
SIGNATURE			
Date	6/29/99		

Burden Hour Statement: this form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.